Zantac recall, divestments and regulations curb Sanofi

8 November 2019 - Deborah Wilkes


Sanofi's Consumer Healthcare business reported worldwide sales up by 0.4% at constant exchange rates in the third quarter of 2019. The company said growth had been curbed by a voluntary recall of Zantac, non-core brand divestments, and tightening regulatory requirements, particularly in Europe.

Click tags below for more information on topics:

Sanofi Consumer Healthcare Ranitidine

Annual Subscription Holder?

Sign in to continue reading.

Sign In

Back to Industry News

Share this page: